Q3 2022 13F Holders as of 9/30/2022
-
Type / Class
-
Equity / COM
-
Number of holders
-
25
-
Total 13F shares, excl. options
-
3.55M
-
Shares change
-
+2.31M
-
Total reported value, excl. options
-
$3.7M
-
Value change
-
+$2.4M
-
Put/Call ratio
-
0.28
-
Number of buys
-
6
-
Number of sells
-
-12
-
Price
-
$1.04
Significant Holders of Protalix BioTherapeutics, Inc. - COM (PLX) as of Q3 2022
35 filings reported holding PLX - Protalix BioTherapeutics, Inc. - COM as of Q3 2022.
Protalix BioTherapeutics, Inc. - COM (PLX) has 25 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 3.55M shares
.
Largest 10 shareholders include HIGHBRIDGE CAPITAL MANAGEMENT LLC (2.41M shares), MEITAV DASH INVESTMENTS LTD (244K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (222K shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (134K shares), RENAISSANCE TECHNOLOGIES LLC (117K shares), BlackRock Inc. (98.8K shares), JANE STREET GROUP, LLC (78.5K shares), CITADEL ADVISORS LLC (58.6K shares), CAPITAL PERFORMANCE ADVISORS LLP (26K shares), and TWO SIGMA ADVISERS, LP (25.3K shares).
This table shows the top 25 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.